Foscarnet sodium
Foscarnet sodium: 1 brand, 7 generics; first approved Sep 27, 1991; generic available.
Generic available: 7 ANDA applications approved.
Brand (NDA) products
- CLINIGEN HLTHCARENDA 02006819912 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/250ML (24MG/ML) SOLUTION INTRAVENOUS Rx AP 12GM/500ML (24MG/ML) SOLUTION INTRAVENOUS Discontinued —
Generic (ANDA) products (7)
- FOSCARNET SODIUMCAPLINANDA 2200682026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/250ML (24MG/ML) SOLUTION INTRAVENOUS Rx AP - FOSCARNET SODIUMAMNEALANDA 2166022024
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/250ML (24MG/ML) SOLUTION INTRAVENOUS Rx AP - FOSCARNET SODIUMSCIECUREANDA 2139872023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/250ML (24MG/ML) SOLUTION INTRAVENOUS Rx AP - FOSCARNET SODIUMAVET LIFESCIENCESANDA 2138072023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/250ML (24MG/ML) SOLUTION INTRAVENOUS Rx AP - FOSCARNET SODIUMGLANDANDA 2130012021
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/250ML (24MG/ML) SOLUTION INTRAVENOUS Rx AP - FOSCARNET SODIUMFRESENIUS KABI USAANDA 2124832021
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/250ML (24MG/ML) SOLUTION INTRAVENOUS Rx AP - FOSCARNET SODIUMHOSPIRAANDA 07717420052 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/250ML (24MG/ML) SOLUTION INTRAVENOUS Discontinued — 12GM/500ML (24MG/ML) SOLUTION INTRAVENOUS Discontinued —
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
Approvals span 1991–2026 across 8 FDA applications.
Foscarnet sodium: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Go beyond the database.
Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.